Michał J. Figurski

发表

Predicting Alzheimer’s disease progression using multi-modal deep learning approach

Sterling C. Johnson, David T. Jones, Nick C Fox, 2019, Scientific Reports.

Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease

Alan C. Evans, Sterling C. Johnson, Keith A. Johnson, 2019, bioRxiv.

A semi-mechanism approach based on MRI and proteomics for prediction of conversion from mild cognitive impairment to Alzheimer’s disease

Sterling C. Johnson, David T. Jones, Nick C Fox, 2016, Scientific Reports.

Robust Identification of Alzheimer’s Disease subtypes based on cortical atrophy patterns

Norbert Schuff, Robert C. Green, Andrew J. Saykin, 2017 .

Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis

Norbert Schuff, Michael W. Weiner, Robert C. Green, 2016, Nature Communications.

The Alzheimer’s Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans

Michael W. Weiner, Andrew J. Saykin, Robert A. Dean, 2015, Alzheimer's & Dementia.

Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer’s pathology

Sterling C. Johnson, David T. Jones, Taylor W. Schmitz, 2016, Nature Communications.

Author Correction: Multimodal hippocampal subfield grading for Alzheimer’s disease classification

Norbert Schuff, Michael W. Weiner, Robert C. Green, 2020, Scientific Reports.

Heritability of regional brain volumes in large-scale neuroimaging and genetic studies

David T. Jones, Nick C Fox, M. Albert, 2017, bioRxiv.

The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory

Sterling C. Johnson, Keith A. Johnson, Joanne L. Lord, 2019, Nature Communications.

18F-florbetapir Positron Emission Tomography–determined Cerebral &bgr;-Amyloid Deposition and Neurocognitive Performance after Cardiac Surgery

David T. Jones, Keith A. Johnson, Jeffrey N. Browndyke, 2018, Anesthesiology.

FAM222A encodes a protein which accumulates in plaques in Alzheimer’s disease

Sterling C. Johnson, David T. Jones, Keith A. Johnson, 2020, Nature Communications.

Comprehensive analysis of epigenetic clocks reveals associations between disproportionate biological ageing and hippocampal volume

Sterling C. Johnson, Keith A. Johnson, Raymond Scott Turner, 2022, GeroScience.

Detection of Alzheimer’s Disease Pathology in patients usingbiochemical biomarkers: prospects and challenges for use in clinicalpractice

J. Trojanowski, M. Korecka, L. Shaw, 2020 .

Featured Articles Improved protocol for measurement of plasma b-amyloid in longitudinal evaluation of Alzheimer's Disease Neuroimaging Initiative study patients

J. Trojanowski, L. Shaw, M. Korecka, 2012 .

Therapeutic drug monitoring of mycophenolic acid.

L. Shaw, Michał J. Figurski, R. Bloom, 2007, Clinical journal of the American Society of Nephrology : CJASN.

An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-ε4 in female patients with Alzheimer’s disease

Sterling C. Johnson, Keith A. Johnson, Raymond Scott Turner, 2022, Nature Aging.

INCLUSION OF PATIENTS WITH ALZHEIMER'S DISEASE PATHOLOGY IN SOLANEZUMAB EXPEDITION 3 USING FLORBETAPIR PET IMAGING OR INNO-BIA ALZBIO3 CSF Aβ1-42

J. Trojanowski, E. Siemers, L. Shaw, 2014, Alzheimer's & Dementia.

Genetic studies of plasma analytes identify novel potential biomarkers for several complex traits

Norbert Schuff, Michael W. Weiner, Robert C. Green, 2016, Scientific Reports.

The impact of P-glycoprotein and Mrp2 on mycophenolic acid levels in mice.

L. Shaw, Michał J. Figurski, Jian Wang, 2008, Transplant immunology.

Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease

Nick C Fox, Keith A. Johnson, Raymond Scott Turner, 2022, Nature Communications.

Development of a Predictive Limited Sampling Strategy for Estimation of Mycophenolic Acid Area Under the Concentration Time Curve in Patients Receiving Concomitant Sirolimus or Cyclosporine

L. Shaw, M. Pescovitz, Michał J. Figurski, 2008, Therapeutic drug monitoring.

High-Performance Liquid Chromatography-Mass Spectroscopy/Mass Spectroscopy Method for Simultaneous Quantification of Total or Free Fraction of Mycophenolic Acid and its Glucuronide Metabolites

L. Shaw, M. Korecka, Michał J. Figurski, 2009, Therapeutic drug monitoring.

Correlation between Alzheimer’s disease and type 2 diabetes using non-negative matrix factorization

Keith A. Johnson, Raymond Scott Turner, Joanne L. Lord, 2021, Scientific Reports.

Women can bear a bigger burden: ante- and post-mortem evidence for reserve in the face of tau

Sterling C. Johnson, Nick C Fox, John X. Morris, 2020, Brain communications.

Qualification of a surrogate matrix-based absolute quantification method for amyloid-β₄₂ in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry.

J. Trojanowski, L. Shaw, M. Grossman, 2014, Journal of Alzheimer's disease : JAD.

Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI

C. Jack, C. DeCarli, M. Weiner, 2011, Acta Neuropathologica.

Ferritin levels in the cerebrospinal fluid predict Alzheimer’s disease outcomes and are regulated by APOE

Keith A. Johnson, Scott Ayton, Joanne L. Lord, 2015, Nature Communications.